Company intelligence / Profile preview

Turning Point Therapeutics, Inc.

San Diego, California, USAnews.bms.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Turning Point’s lead asset repotrectinib demonstrated longer duration of response than existing ROS1 agents in first-line NSCLC in the TRIDENT‑1 trial and received three FDA Breakthrough Therapy Designations. Other pipeline assets showed promising early clinical activity against genetically defined solid tumors[3][6][9].

Therapeutic areas: Oncology
Modalities: small molecules (macrocyclic tyrosine kinase inhibitors)antibody-drug conjugates (ADC)
Industry: Biotech

Drug pipeline

4 assets

repotrectinib

Phase 2

Indications: ROS1-positive non-small cell lung cancer, Advanced solid tumors

3 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb (since August 2022)Zai Lab (China rights to repotrectinib)

Beyond the preview

Go deeper on Turning Point Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turning Point Therapeutics, Inc..

Explore the full profile